Please find attached press release on financial results of the Company for Q1FY27
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 30 Jul 2026, 03:54 PM IST · BSE ID: 49824c01-0b28-4a66-8d27-019c905fbf62
View Original BSE Filing (PDF)
💡
In Simple Terms
Mankind Pharma's Q1 FY27 profit and total sales increased by 29.1% and 12.9% respectively.
🤖 AI Summary
- Mankind Pharma's PAT for Q1 FY27 increased by 29.1% YoY to INR 574 Crore.
- Revenue from Operations for Q1 FY27 reached INR 4,031 Crore, marking a 12.9% YoY growth.
- Domestic revenue grew 10.5% YoY to INR 3,426 Crore, with Exports increasing 29.0% YoY to INR 605 Crore.
- EBITDA margin improved by 250 bps YoY to 26.3% and PAT margin by 170 bps YoY to 14.2% in Q1 FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations
INR 4,031 Crore
12.9%
EBITDA Margin %
26.3%
250 bps
Domestic Revenue
INR 3,426 Crore
10.5%
Exports
INR 605 Crore
29.0%
Diluted EPS
INR 13.7
29.6%
🏢 How This Affects the Company
The company reported 11.0% growth in its domestic business (excluding Consumer Healthcare) and 29.0% growth in its International business for Q1 FY27, indicating continued market presence and expansion. Double-digit growth in chronic segments like cardiac (19.4%) and anti-diabetes (12.7%) strengthened its position in these therapeutic areas.
Consolidated PAT increased by 29.1% YoY to INR 574 Crore and Revenue from Operations grew 12.9% YoY to INR 4,031 Crore. EBITDA margin improved by 250 bps to 26.3% and PAT margin by 170 bps to 14.2%, reflecting improved profitability.
Disciplined execution and strengthening business fundamentals contributed to improvements in key operating metrics, supporting sustained growth. The company maintained its #1 rank over the last 9 years with a prescription share of 15.2% (as per IQVIA Jun-2026).
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results press release.
👤
Who Is Affected
All shareholders are affected as these are consolidated financial results reflecting the company's overall performance. Earnings Per Share (Diluted EPS) increased by 29.6% YoY to INR 13.7 (FV Re.1) for Q1 FY27.
🔍
Management Signal
The management's statements highlight disciplined execution and strengthening business fundamentals as key drivers for improvements in operating and financial metrics.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check for sustained revenue and margin growth
Update on domestic business growth, particularly in chronic segments
Further details on performance of international business and new product launches
LOW RISK
The filing indicates strong financial performance with no specific risks highlighted.
💡 Investor Takeaway
Mankind Pharma reported Q1 FY27 PAT of INR 574 Crore, a 29.1% YoY increase, with Revenue from Operations reaching INR 4,031 Crore, up 12.9% YoY. EBITDA margin improved by 250 bps to 26.3%, and exports grew 29.0% YoY to INR 605 Crore, confirming strong financial performance.
⚖️ Strengths & Concerns
✅ Positives
- PAT increased by 29.1% YoY to INR 574 Crore in Q1 FY27, indicating strong profitability compared to the prior year period.
- EBITDA margin improved by 250 bps YoY to 26.3% in Q1 FY27, reflecting enhanced operational efficiency.
⚠️ Concerns
- Consumer Healthcare revenue growth was 3.9% YoY in Q1 FY27, partly impacted by the base effect of discontinued cash and carry business.
- Domestic revenue growth of 10.5% YoY was lower than overall Revenue from Operations growth of 12.9% YoY for Q1 FY27.
📅 Company Track Record
Previous filings indicated Mankind Pharma's Q1 FY27 profit rose 34.49% to Rs. 558.49 crore. This press release confirms a 29.1% increase in PAT to INR 574 Crore, aligning with prior intimation of strong quarterly performance.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Mankind Pharma's net profit in Q1 FY27?
Mankind Pharma's net profit (PAT) for Q1 FY27 was INR 574 Crore, a 29.1% increase compared to INR 445 Crore in Q1 FY26.
What was Mankind Pharma's total revenue in Q1 FY27?
Mankind Pharma's Revenue from Operations for Q1 FY27 was INR 4,031 Crore, an increase of 12.9% from INR 3,570 Crore in Q1 FY26.
How did Mankind Pharma's domestic and international revenues perform in Q1 FY27?
Domestic revenue grew 10.5% YoY to INR 3,426 Crore, and exports increased by 29.0% YoY to INR 605 Crore in Q1 FY27.
What was Mankind Pharma's EBITDA margin in Q1 FY27?
Mankind Pharma's EBITDA margin for Q1 FY27 was 26.3%, an improvement of 250 basis points compared to 23.8% in Q1 FY26.
What was the Diluted EPS for Mankind Pharma in Q1 FY27?
The Diluted EPS for Mankind Pharma in Q1 FY27 was INR 13.7, which is a 29.6% increase YoY.
Questions based on this BSE filing only. For information purposes.